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Bimodal fluorogenic sensing of matrix proteolytic
signatures in lung cancer†
Alicia Megia-Fernandez, ‡a Bethany Mills, ‡b Chesney Michels,b
Sunay V. Chankeshwara, a Nikola Krstajić, c Chris Haslett,b Kevin Dhaliwal *b
and Mark Bradley *a
Optical biosensing based on the activation of fluorescent reporters offers a powerful methodology for the
real-time molecular interrogation of pathology. Here we report a first-in-class, bimodal fluorescent repor-
ter strategy for the simultaneous and highly specific detection of two independent proteases (thrombin
and matrix metalloproteases (MMPs)) pivotal in the fibroproliferative process surrounding lung cancer,
based on a dual, multiplexing, peptide FRET system. This sophisticated synthetic smartprobe, with a mole-
cular weight of 6 kDa, contains two independent fluorophores and quenchers that generate photonic sig-
natures at two specific wavelengths upon activation by target enzymes within human lung cancer tissue.
Introduction
Lung cancer is the leading cause of cancer death in the world
and most patients present with late stage disease due to a pro-
tracted diagnostic pathway.1 There have been major advances
in interventional approaches for sampling suspected lung
cancer in the distal lung that are augmented by routinely
employed navigational technologies and the emergence of
fibre based optical approaches.2–4 We have previously
described the use of such platforms for guiding biopsy but a
major limitation remains the lack of molecular probes to high-
light suspected tumours and to guide sampling.5 Lung cancer
is characterised by significant enzymatic activity in the penum-
bra and we sought to develop and validate a unique chemical
probe with bimodal photonic amplification which had signifi-
cant advantages over classical individual reporters.
Biosensing of enzymatic activity has been at the focus of
significant chemical and clinical advances,6–8 with fluorescent
probes reporting protease activity in vivo, including the
cathepsins,9–11 caspases,12 enzymes of the coagulation
cascade13 and those responsible for matrix remodelling.14
Many of these probes are peptide-based, often exploiting the
FRET (Förster Resonance Energy Transfer) phenomenon to
detect enzymatic activity.13,15 Optical-imaging probes based on
fluorescence offer the possibility of optical multiplexing but
previous reports utilizing fluorescent probes for multi-analyte
detection have principally focused on the sequential activation
of a single fluorophore with enzymes working in series16 or for
the detection of metal ions and small molecules such as H2O2,
NO or H2S,
17,18 with the few reported examples of multienzy-
matic detection strategies relying on the turn-on of a single
caged fluorophore.19
Our aim in this work was to develop the chemical tractabil-
ity and advance a strategy for the simultaneous analysis of
multiple molecular targets in lung cancer tissue which has sig-
nificant advantages over independent sensors or sequential
sensing. To date, there are no reports of probes that can inde-
pendently report on two different enzyme activities simul-
taneously using a single chemical entity and at two different
wavelengths, and no such multi-enzyme sensing has been
reported in human lung cancer. To achieve this, we combined
four optical entities (two fluorophores and two quenchers) in a
single molecule to yield a biologically robust, highly sensitive
and specific FRET dual-enzyme reporter, with the key deliver-
able of high substrate-specificity over by-stander enzymes,
while functioning within the environment of ex vivo human
diseased tissue.
The focus for our dual-enzyme sensor were key enzymes in
the inflammatory cascade surrounding lung cancer,20–22
thrombin and matrix metalloproteinases-2, -9 and -13 (MMP-2,
-9 and -13).23–26 Thrombin and the MMPs are two distinct
classes of proteolytic extracellular proteins that play important
temporal roles in fibroproliferation and coagulation,20–22
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which may lead to dysregulation of the extracellular matrix
(ECM). They have key roles in early carcinogenesis, in promot-
ing early tumour–platelet interactions and have an association
with pulmonary metastases. They are highly overexpressed in
the malignant matrix and in fibrosis,26–28 and as such are




All experiments using human samples in vitro were performed
following approval of the appropriate regional ethics commit-
tee (REC), NHS Lothian (references 13/ES/0126 and 15/HV/
013), and with informed consent of the patients. All murine
experiments were performed under UK Home Office license
60/4434.
Statistical analysis
Statistical analyses were performed using Prism 7 (GraphPad
Software Inc., La Jolla, CA, USA). Where appropriate, analyses
were performed using the student’s t-test or one-way ANOVA.
Unless otherwise stated error bars show standard error of the
mean (s.e.m).
Synthesis and characterization
Synthetic procedures and full characterization of compounds
1–5 and intermediates are described in the ESI.†
Enzymatic validation of dual-probe 3
To determine the enzymatic specificity of the dual-probes 1–5
(fragments b and f, and peptides undergoing optimisation as
outlined in the ESI†) the probes were incubated at a concen-
tration of 5 µM (unless otherwise stated) with the required
recombinant MMP enzymes (Enzo Life Sciences) (active
domains of MMP-1, -2, -3, -7, -8, -9, -10, -11, -12 and -13, 30
nM), thrombin (Sigma Aldrich) (5 U ml−1), Factor Xa (Sigma
Aldrich) (500 nM), Plasmin (Sigma Aldrich) (30 nM), and
human neutrophil elastase (30 nM). Where enzymes were
added sequentially to dual-probe 3, the first enzyme was incu-
bated with the probe for 60 min prior to the addition of the
second enzyme. Data was collected from 10 min incubation of
probe with enzyme. Where appropriate enzymes were incu-
bated with specific inhibitors for 30 min at 37 °C prior to
addition of the dual-probe 3. The pan-MMP inhibitor
Marimastat (Tocris Biosciences) was used at 20 µM, while the
thrombin inhibitor (anti-thrombin III (AT3, Sigma Aldrich))
was pre-incubated at 1 µM. Enzyme free reactions served as a
control. Enzymatic reactions were performed in MMP buffer
(10 mM CaCl2, 6.1 g Tris-HCl, 8.6 g NaCl per litre, pH 7.5) in a
final volume of 20 µL. Reactions were performed in duplicate
in 384 well plates (Life Technologies) with optically clear plate
seals (Thermo Scientific) and repeated thrice (independently).
Fluorescence signal was measured for up to 60 min, ex/em
485/528 nm (FAM) and ex/em 640/670 nm (Cy5) using micro-
plate reader (BioTek Synergy H1 multi-mode reader). Data was
normalised to buffer alone and are presented as fold-change
in signal (Relative Fluorescent Units) compared to enzyme-free
controls at 10 min. Data was plotted using Prism 7 (GraphPad
Software Inc., La Jolla, CA, USA).
Neutrophils and platelet rich plasma extraction
Platelet rich plasma (PRP) and neutrophils were isolated from
the blood of healthy human volunteers as previously
described.29 PRP was collected after initial centrifugation step
of whole blood and stored at −20 °C until use. The number of
retrieved neutrophils was determined with NucleoCounter
NC-1000 (Chemo Metec). Neutrophils were resuspended at a
concentration of 20 × 106 mL−1 in 0.9% NaCl with 0.9 mM
CaCl2. Cells were incubated for 30 min at 37 °C. Cells to be
stimulated were subsequently activated with 5 µM calcium
ionophore A23187 (Tocris Bioscience) for 30 min at 37 °C.
Neutrophils were harvested by centrifugation at 400g for
5 min. Supernatants were removed and stored. Plate reader
assays were performed as described above, with the MMP
buffer replaced with neutrophil supernatant or PRP. All experi-
ments were carried-out in duplicate using three independent
donors (one donor per independent repeat). Data was normal-
ised by background subtraction of intrinsic fluorescence.
Atherosclerotic plaque imaging
Human carotid plaques were stored in 0.9% NaCl on ice
immediately following excision. All samples were used within
2 h of retrieval. Carotid plaques were sliced in half lengthwise
and placed into wells of a 6-well plate. 2 mL of 5 µM ice-cold
dual-probe 3 was added to the well containing the carotid
plaque, and an adjacent control well. Fluorescence intensity
was imaged over 60 minutes using a Photon-Imager Optima
System (Biospace Lab) set to detect FAM and Cy5 fluorescence.
After 60 min, the plaque was removed from the well and the
plate was imaged again to compare the fluorescent signal from
within the well for sample and control wells. Images were ana-
lysed using M3 Vision software (Biospace Lab). Regions of
interest (ROIs) were drawn around entire wells and fluo-
rescence intensity p s−1 cm−2 sr−1 were determined. Data was
collected from 3 independent carotid plaques. Solutions from
the carotid plaque well and control wells were retrieved and
analysed by MALDI-TOF MS.
Lung tissue imaging
Human lung tissue (adenocarcinoma tumour and normal
tissue from a site separate to the tumour location) were
obtained following surgical resection and stored at −80° C
until use. The tissue was sliced into 1 × 4 mm2 sections and
placed in the wells of a 96-well plate with 100 µL MMP buffer.
Where appropriate, marimastat (50 µM) and AT3 (1 µM) were
added to the tissue and incubated at 37 °C for 60 min prior to
the addition of dual-probe 3 (5 µM). The tissue was imaged
over 30 min using a wide-field microendoscopy fluorescent
imaging system as previously reported30 with a clinically
approved commercial imaging fibre (Alveoflex, Mauna Kea
Paper Organic & Biomolecular Chemistry























































































Technologies). At each time point 10 s of images were taken
with a 25 ms exposure time, at 10 frames per second, with
LEDs aligned for FAM and Cy5 detection. Average fluorescence
for each sample was calculated by determining the average
fluorescence per frame for each time point (55 median frames
out of 75 frames collected per time point). All images were
brightness and contrast enhanced with the same parameters.
A single patient specimen was collected and analysed.
Murine LPS model
The murine LPS model is outlined in the ESI.†
Results and discussion
Design, synthesis and initial validation of the dual-probe
Our novel FRET based dual-probe incorporated highly opti-
mised thrombin and MMP peptide based-substrates (see ESI†),
as well as two strategically placed fluorophores and two
quenchers (Fig. 1), allowing the release of specific fluorescent
fragments that could be detected at different wavelengths, with
5-FAM/Methyl Red and Cy5/QSY21 fluorophore/quencher pairs
chosen for the thrombin and MMP fragments respectively. In
addition, both fluorophores were strategically placed to ensure
that following cleavage they remained within the liberated
hydrophilic tail. The rationale for the chosen dye/quencher
pairs were based upon their well differentiated emission wave-
lengths and minimal spectral overlap. It was considered for its
use within the multi-colour microendoscopy imaging system
(with appropriate LEDs for FAM and Cy5 excitation). A number
of peptide sequences and scaffold structures were iterated and
evaluated (Table 1) to yield the final optimised dual-probe 3
(Fig. 1ii). The peptide sequence for thrombin was selected fol-
lowing a lead optimisation programme;31 while the optimised
peptide sequence for MMP-2, -9 and -13 was selected after
extensive screening as detailed in the ESI.† The initial dual-
probe synthesized (dual-probe 1) was cleaved by thrombin and
MMP-2, -9 and -13 but was shown to have very poor plasmin
stability (Fig. S1†) a major issue, as this is an abundant pro-
tease in vivo and this protease undoubtedly cleaves many
Fig. 1 Design, synthesis, structures and quenching of the dual-probes. (i) Synthesis and mode of action of the dual-probe for thrombin (Thm,
Table 1 – sequence 1) and matrix metalloproteases (MMP-2, -9 and -13, Table 1 – sequence 2). (ii) Full structure of compound 3. For clarity the
thrombin substrate (with associated X1 group and tail) is drawn in an unconventional C → N orientation. (iii) Reverse phase HPLC analysis (λ 500 nm)
of the fragments (b and f ) showing the rapid and clean conjugation to generate dual-probe 3. (iv) The background fluorescence of fragments b, f,
and dual-probe 3 were measured to determine the extent of FRET quenching for each of the fluorophores [ex/em 485/528 nm (FAM) and 640/
670 nm (Cy5)]. Data is the mean of three independent replicates performed in duplicate. Error bars represent s.e.m. Statistical analysis was performed
with a one-way ANOVA test, **** P < 0.0001.
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Table 1 Showing the peptide sequences and spacers incorporated into dual-probe scaffold
Compound Sequence 1 (thrombin substrates) Sequence 2 (MMP substrates) X2
1 –NleWPRGWRL –GPKGLKG– –K(PEG2)-PEG2–
2 –NleWPRGWRL– –PFGNleKβA– –K(PEG2)-PEG2–
3a –NleWPRGWR(D)L– –PFGNleKβA– –K-PEG2–
4a –NleWP(D)RGWR(D)L– –PFGNleKβA– –K-PEG2–
5a –NleWPRGWR(D)L– –PFG(D)NleKβA– –K-PEG2–
a
D-Aminoacids D-Leu, D-Arg and D-Nle were used where indicated. X1: –PEG2-K(–CO(CH2)2–CuCH). Tail: -[PEG2-(D)Lys]3-NH2; Nle:Norleucine.
Fig. 2 Dual-probe 3 was cleaved by target (i) thrombin and (ii) MMPs, specificity was confirmed by MALDI TOF MS. (a) Dual-probe 3 was incubated
with target and off-target enzymes, with or without inhibitor. Activation was determined by measuring the fluorescence increase (compared to
enzyme-free control) at 10 min at two different wavelengths (ex/em 485/528 nm (FAM) and 640/670 nm (Cy5)). (b) The fold-change in fluorescence
intensity of fragments b, f and dual-probe 3 were compared following activation with MMP-9 or thrombin, with probe 3 showing specific FAM acti-
vation with thrombin and Cy5 increasing with MMP-9 (c) structure of dual-probe 3 showing the theoretical molecular weights of the fragments
obtained following cleavage; (d) MALDI-TOF MS spectra of 3 before and after treatment with thrombin or MMP-9. The initial peak for 3 at m/z
6182.001 Da (calc. for C307H427N64O67S3
+ [M+]: 6182.353 Da) disappears following treatment showing two new peaks with the expected m/z. (e)
MALDI-TOF MS (m/z 1500–3000 Da) correlates well with the expected fragments even when the two enzymes act together. Data is the mean of
three independent replicates performed in duplicate. Error bars represent s.e.m. Statistical analysis was performed with one-way ANOVA test.
(a) * P = 0.0225; ** P = 0.0026; **** P < 0.0001. (b) P** = 0.0018; *** P = 0.0004; **** P < 0.0001.
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previously reported MMP probes. The MMP peptide sequence
was developed to give dual-probe 2 (changing the peptide
sequence from GPKGLKG to PFGNleKβA – see ESI†) which
resulted in plasmin stability whilst preserving target MMP clea-
vage specificity. However non-specific cleavage of the thrombin
peptide in dual-probe 2 by plasmin was still observed (Fig. S1†),
thus this dual-probe underwent further iteration, substituting
the L-leucine residue with D-leucine (NleWPRGWR(D)L) to yield
the plasmin inert but thrombin responsive, dual-probe 3.
The two lead optimized FRET peptides for thrombin and
MMP described above (fragments b and f, Table S2†) were sep-
arately synthesized by Fmoc solid-phase peptide chemistry
(Scheme S1†). The dyes and quenchers were coupled onto the
peptides by solid-phase methods, with the Dde32 group used
to allow late stage fluorophore incorporation, whilst the
quenchers were added onto the amino termini of each
peptide. In both cases C-terminal spacers consisting of bis-
PEG units and (D)-Lys were incorporated; providing a hydro-
philic unit to promote solubility and preventing exopeptidase
degradation, and again, were incorporated as a result of an
extensive screening study (see details in the ESI†) to stop
degradation via enzymes present in homogenized human
tissue. Following cleavage from the resin, the two peptides
were purified and azide/alkyne coupling of the two unpro-
tected fragments was achieved under aqueous conditions,33
allowing efficient conjugation in 5 hours via generation of a
biocompatible 1,2,3-triazole (Fig. 1ii and iii), and giving com-
pounds 1–3 (Fig. 1, Table 1). Importantly, combining frag-
ments b and f onto one scaffold to give dual-probe 3 provided
enhanced quenching of each of the fluorophores (Fig. 1iv) and
showed increased dequenching and improved signal-to-noise
upon proteolytic cleavage compared to the individual frag-
ments (Fig. 2). Compounds 4 and 5 were prepared incorporat-
ing D-aminoacids into the cleavage site for each enzyme to
provide non-cleavable control compounds (Fig. 1, Table 1).
The final constructs have molecular weights of 6.1–6.4 kDa
and represent highly refined, sophisticated, selective and sen-
sitive optical probes.
The enzymatic cleavage of the dual-probe was specific; with
MALDI-TOF MS confirming cleavage between –Gly↑Nle by
MMPs and between Arg↑Gly by thrombin (see Fig. 2). This was
also shown by HPLC analysis (Fig. S3b†). Activation of dual-
probe 3 was prevented by marimastat (a pan-MMP inhibitor)
and anti-thrombin III (AT3) (Fig. 2). Control dual-probes 4 and
5 (Table 1) were not activated by their target enzymes, confirm-
ing enzyme specificity (Fig. S4†).
Dual-probe 3 was stable for over two months in PBS at
room temperature (Fig. S2†), optically silent prior to activation
(Fig. S3a†) and completely plasmin and Factor Xa resistant,
whilst retaining its ability to be activated by target enzymes –
showing high signal to noise (Fig. 2a). Within 10 minutes of
enzyme addition to dual-probe 3, Cy5 signal increased 5.6, 4.6
and 27.4-fold by the active domains of MMP-2, -9 and -13
respectively, while the FAM signal increased 6.2-fold following
the addition of thrombin with the fold-changes in fluorescence
superior to those of individual thrombin and MMP com-
Fig. 3 Dual-probe 3 was cleaved selectively by: (a) activated neutrophil
supernatant and (b) Platelet rich plasma (PRP). Cleavage and subsequent
activation was determined by measuring the relative fluorescence
increase (compared to enzyme-free control). Data shows mean of three
independent replicates performed in duplicate ((a) 20 and 60 min time
points for neutrophil assay, (b) 60 min time point for PRP assay). Error
bars represent s.e.m. Statistical analysis was performed with one-way
ANOVA test, enzyme columns were compared directly to enzyme plus
inhibitor conditions. ** P < 0.01; *** P < 0.0001; **** P < 0.0001.
Fig. 4 Dual-probe 3 was specifically activated by excised atherosclero-
tic plaques. (a) Representative image of excised atherosclerotic plaque.
Scale bar 5 mm. (b) Cleavage and subsequent activation of dual-probe 3
by atherosclerotic tissue was determined by measuring relative fluor-
escence increase at ex/em 485/528 nm (FAM) and 640/670 nm (Cy5)
over 60 min. (c) Fold-change in fluorescence over 60 min. Data is the
mean of three independent samples. Error bars represent s.e.m. (d)
MALDI-TOF MS analysis was performed after incubation with the athero-
sclerotic plaque. The peak at 2459.9 Da indicates combined thrombin
and MMP cleavage (Fig. 2 and Fig. S6† for further detail).
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pounds b and f (Fig. 2b). Vitally, no signal increase was
observed as a consequence of cross-enzyme reactivity, and no
steric hindrance was seen when cleaving the dual-probe with
MMP and thrombin either simultaneously (Fig. 2a), or sequen-
tially (Fig. S3c†).
Human tissue validation
Dual-probe 3 was subsequently evaluated in escalating ex vivo
human primary tissue models to demonstrate stability within
complex microenvironments and activation of the dual-probe
with biologically relevant levels of target enzyme. This
included activated primary isolated human neutrophils,
primary human platelet rich plasma (PRP) (Fig. 3 and S5, out-
lined in ESI†), human atherosclerotic plaque and finally to
show proof of concept, human lung adenocarcinoma samples.
Human atherosclerotic plaques have a biologically complex
microenvironment, with MMPs and thrombin in high abun-
dance.34,35 These were thus used as a relevant non-cancer
model to validate dual-probe 3 (Fig. 4). Activation of the dual-
probe by the endogenous enzymes was measured by fluo-
rescence imaging of the supernatant after 60 min (Fig. 4b).
Fluorescence emitted by dual-probe 3 incubated with tissue
samples increased in both the FAM and Cy5 channels (Fig. 4c)
with MALDI-TOF MS analysis confirming that activation was
specific, with fragments of 1837 Da (thrombin cleavage) and
2459 Da (thrombin + MMP cleavage) detected (Fig. 4d,
Fig. S6†). Where no tissue was present, only intact probe was
identified by MALDI-TOF MS and no increase in fluorescence
was detected. Whilst fold-changes in fluorescent signal were
observed to be modest when imaging with this widefield tech-
Fig. 5 Specific activation of dual-probe 3 was measured in human lung adenocarcinoma with a clinical optical fibre-based imaging device, ± inhibi-
tors. Average fold-change in fluorescence for each tissue type was calculated for each time point for the FAM and Cy5 signal. Images show repre-
sentative single frames from the imaging system, while graphs show calculated fold-change in average fluorescence. Error bars show s.e.m,
**** p < 0.0001. Statistical analysis was performed with one-way ANOVA test.
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nique (reasons for which are outlined in the ESI-Fig. S6†), acti-
vated dual-probe 3 from these clinical samples was detected by
both optical imaging and MALDI-TOF MS analysis.
An initial clinical use of dual-probe 3 could be in the rapid
identification of fibroproliferative enzymes around human
lung adenocarcinoma in situ; where the dual-probe could be
locally delivered and immediately imaged by a multi-colour
fibre-based imaging system during an interventional procedure
such as bronchoscopy or image-guided biopsies.30 Typically
pulmonary microendoscopy of suspected lung cancer is ham-
pered by the lack of molecular tracers to augment tissue auto-
fluorescence signatures.5 Combining local intrapulmonary
delivery of dual-probe 3 with multi-colour microendoscopy
could significantly enhance clinical diagnostic capability.
Within 5 min of dual-probe 3 addition to human lung adeno-
carcinoma tissue ex vivo, a 2.1 and 14.7-fold increase in FAM
(thrombin) and Cy5 (MMP-13, -9, -2) signal was measured
using a clinically approved fibre-based imaging system.30 The
fold-change increased to 3.8 and 32.2-fold at 30 min (Fig. 5).
The increase in fluorescence was not apparent when thrombin
and MMP inhibitors were added to the tissue, and fold-
changes from native tumour tissue were significantly elevated
compared to those measured from the dual-probe on ‘healthy’
lung tissue (p < 0.0001), which was collected from the same
patient, but from an area distinct from the tumour. Thus sup-
porting the use of dual-probe 3 to highlight aberrant matrix
activity as an aid in guiding biopsy and in ‘red flagging’ a
lesion as suspicious; a major advancement in the field of pul-
monary endomicroscopy, required as we head towards a future
of ‘optical biopsy’ and guided interventional procedures.5,36
Conclusions
In summary, we have developed a novel FRET-based dual-
probe that can simultaneously detect human thrombin and
MMP activity, with reporting at two spectrally distinct wave-
lengths. It was synthesised as two component halves and
efficiently brought together using azide/alkyne cycloaddition
chemistry to give a sophisticated synthetic dual imaging
probe. This dual-probe shows long-term stability, and despite
its size and complexity, the optimized synthetic strategy is
practical and readily scalable. The dual-probe was specifically
designed for human clinical translation and was not activated
by murine proteolytic enzymes; as evidenced by using lavage
supernatants from murine models and using murine platelet
rich plasma (see Fig. S7†), highlighting the significant caveats
of using murine models as experimental systems to support
human translation.
The probe exhibits an increase in florescence upon acti-
vation by target MMPs and thrombin which was detectable by
all currently available detection systems used in the experi-
mental evaluation. However, there are potential challenges as
with any biosensor in achieving an appropriate limit of detec-
tion (LoD) in vivo. In vivo in situ, the LoD is unknown and
likely to be highly variable regarding expression of enzyme
activity, and to date, non-quantitative immunohistochemistry
and gene expression have been used in lung cancers to quan-
tify presence rather than kinetic enzyme determination.
However, in non-small-cell lung carcinoma, MMP13 has been
shown to be consistently and ubiquitously expressed.37
Ultimately the LoD will need to be evaluated in formal pro-
spective diagnostic studies, however excitingly, with more sen-
sitive detectors that are capable of measurements independent
of fluorescent intensity that are now emerging,38 we expect
this to be ample for detection.
The incubation of dual-probe 3 within escalating human
relevant environments described here demonstrates that the
dual-probe possessed excellent stability, specificity and under-
went highly selective activation. Due to the superior stability,
specificity and signal-to-noise of our novel dual-probe com-
pared to those reported within the literature, we believe that
this dual-probe has potential to be used as a tool to identify
multiple biomarkers of the fibroproliferative pathway in fluid
and tissue samples ex vivo, but more importantly in the future
with further translational development, in situ in vivo optical
imaging. In addition, the platform approach lends itself to ver-
satile insertion of other peptide substrates to generate future
multiplexed chemosensors of enzyme activity.
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